| Literature DB >> 33788386 |
Robert J Shmookler Reis1,2,3, Ramani Atluri2, Meenakshisundaram Balasubramaniam2, Jay Johnson3, Akshatha Ganne3, Srinivas Ayyadevara1,2.
Abstract
All neurodegenerative diseases feature aggregates, which usually contain disease-specific diagnostic proteins; non-protein constituents, however, have rarely been explored. Aggregates from SY5Y-APPSw neuroblastoma, a cell model of familial Alzheimer's disease, were crosslinked and sequences of linked peptides identified. We constructed a normalized "contactome" comprising 11 subnetworks, centered on 24 high-connectivity hubs. Remarkably, all 24 are nucleic acid-binding proteins. This led us to isolate and sequence RNA and DNA from Alzheimer's and control aggregates. RNA fragments were mapped to the human genome by RNA-seq and DNA by ChIP-seq. Nearly all aggregate RNA sequences mapped to specific genes, whereas DNA fragments were predominantly intergenic. These nucleic acid mappings are all significantly nonrandom, making an artifactual origin extremely unlikely. RNA (mostly cytoplasmic) exceeded DNA (chiefly nuclear) by twofold to fivefold. RNA fragments recovered from AD tissue were ~1.5-to 2.5-fold more abundant than those recovered from control tissue, similar to the increase in protein. Aggregate abundances of specific RNA sequences were strikingly differential between cultured SY5Y-APPSw glioblastoma cells expressing APOE3 vs. APOE4, consistent with APOE4 competition for E-box/CLEAR motifs. We identified many G-quadruplex and viral sequences within RNA and DNA of aggregates, suggesting that sequestration of viral genomes may have driven the evolution of disordered nucleic acid-binding proteins. After RNA-interference knockdown of the translational-procession factor EEF2 to suppress translation in SY5Y-APPSw cells, the RNA content of aggregates declined by >90%, while reducing protein content by only 30% and altering DNA content by ≤10%. This implies that cotranslational misfolding of nascent proteins may ensnare polysomes into aggregates, accounting for most of their RNA content.Entities:
Keywords: Alzheimer’s disease; DNA; RNA; aggregation; apolipoprotein E; beta amyloid; cotranslational misfolding; endogenous viruses; functional annotation; gene ontology; neurodegeneration; nucleic acid sequence; nucleic acids; protein aggregates; proteomics; retrotransposons
Mesh:
Substances:
Year: 2021 PMID: 33788386 PMCID: PMC8135009 DOI: 10.1111/acel.13326
Source DB: PubMed Journal: Aging Cell ISSN: 1474-9718 Impact factor: 9.304
FIGURE 1The “aggregate contactome” of proteins isolated from SY5Y‐APPSw human neuroblastoma cells, an in vitro model of familial AD. The contactome was generated from proteomic data for cross‐linked peptide pairs in sarkosyl‐insoluble aggregates, using a modified version of X‐link Identifier (Balasubramaniam et al., 2019; Du et al., 2011), requiring ≥10 spectral hits per protein observed in at least 2 of 3 replicate crosslinking experiments. Hits were normalized to hub length (amino acids in the most abundant isoform). Red circles highlight central hubs with 5 or more large‐hub interactors; green circles show smaller hub‐connectors, which join major hubs not otherwise connected. Other proteins of interest are indicated by dashed gray circles
FIGURE 2Recovery of DNA and RNA from aggregates. DNA and RNA were extracted and quantified from insoluble aggregates, isolated from hippocampi of AMC (APOE ε3/ε3), or AD (ε3/ε3 or ε4/ε4) individuals (A, each N = 3); or from similar mixes of APOE ε3/ε3 and ε3/ε4 individuals (B, each N = 5–6). (C, D) DNA and RNA were extracted from insoluble aggregates from T98G glioma cells. C, independent cultures of T98G cells overexpressing APOE ε3 from a transgene were compared to cultures expressing ε4. D, T98G cells without any transgene were lysed in 0.5% NP40, and nuclei separated from cytoplasm. DNA was chiefly associated with nuclear aggregates, and RNA with cytoplasmic aggregates, as expected. Means ±SDs are shown. p values reflect 2‐tailed heteroscedastic t tests.
DNA Fragments Recovered from AD, AMC Aggregates (ChIP‐seq analysis)
| Chrom. | Region | Length | 5’ Gene | 5’ distance | 3’ Gene | 3’ Distance | AD Peaks | AMC Peaks | AD Peak | AMC Peak | Gene Description (Nearest Gene) |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 633735..634300 | 566 | RP5‐857 K21.3 | 36236 |
| 0 | 1 | 4 | 4. E−02 | 4. E−06 | Transcribed processed pseudogene; also in all aggregate RNAs |
|
| 143202361..143202903 | 543 | RP11‐344P13.1 | 21621836 | CH17‐333 M13.2 | 140276 | 56 | 51 | 3. E−29 | 9. E−31 | |
|
| 32916116..32916684 | 569 |
| 0 | AL121656.5 | 10442 | 2 | 2 | 4. E−11 | 2. E−13 | Long Intergenic Non‐Protein‐Coding RNA 486; also in all aggregate RNAs |
|
| 89830806..89831378 | 573 | 5S_rRNA | 230125 | IGKV2D−40 | 20412 | 11 | 11 | 2. E−05 | 9. E−06 | |
|
| 75668953..75669543 | 591 |
| 0 | LINC00960 | 2847 | 1 | 1 | 4. E−11 | 4. E−11 | Double Homeobox 4‐Like 26 |
|
| 93470298..93470861 | 564 | HSPE1P19 | 3208589 | RNU6‐488P | 372902 | 2 | 1 | 6. E−57 | 1. E−63 | |
|
| 49149228..49149839 | 612 | TPI1P4 | 132073 | AC118282.3 | 47363 | 34 | 27 | 9. E−11 | 1. E−09 | |
|
| 49711347..49711912 | 566 | AC119751.4 | 111837 | DCUN1D4 | 2131087 | 13 | 18 | 9. E−16 | 7. E−18 | |
|
| 190179314..190179950 | 637 | AC215524.1 | 4089 | ABC7‐42391500H16.3 | 5896 | 3 | 3 | 2. E−13 | 3. E−13 | |
|
| 49661354..49661926 | 573 | CTD−2013 M15.1 | 3765383 | EMB | 734265 | 15 | 13 | 2. E−11 | 1. E−10 | |
|
| 61322762..61323316 | 555 | RP1‐91 N13.1 | 81450 | MTRNR2L9 | 251011 | 1 | 1 | 3. E−02 | 3. E−06 | |
|
| 59995570..59996144 | 575 | RP11‐548 K12.13 | 2159318 | RP11‐715L17.1 | 2279216 | 0 | 9 | no peak | 2. E−03 | |
|
| 43237602..43238166 | 565 | VN1R46P | 16792 | RP11‐726G23.2 | 8588 | 4 | 4 | 4. E−08 | 4. E−09 | |
|
| 70038064..70038625 | 562 | RN7SL570P | 153409 |
| 0 | 1 | 1 | 8. E−07 | 1. E−05 | MAM Domain Containing 2 (antisense strand) |
|
| 42070370..42070986 | 617 | RP11‐96F8.1 | 3287261 | KSR1P1 | 78323 | 39 | 35 | 9. E−06 | 2. E−04 | |
|
| 133688058..133688661 | 604 | AL845259.2 | 2945 | DUX4L29 | 51944 | 2 | 2 | 2. E−05 | 3. E−04 | |
|
| 35614697..35615271 | 575 | AK6P1 | 1364738 | RP11‐125 N22.4 | 1926740 | 1 | 1 | 8. E−03 | 5. E−05 | |
|
| 18211736..18212297 | 562 | AL356585.2 | 4266 | RP11‐341D18.4 | 41228 | 1 | 1 | 2. E−11 | 6. E−25 | |
|
| 34063731..34064293 | 563 | RP11‐598D12.2 | 12369 | CTD−2522B17.8 | 56176 | 5 | 5 | 7. E−05 | 2. E−04 | |
|
| 34587942..34588505 | 564 | BCLAF1P2 | 319292 | CTD−2144E22.9 | 353471 | 15 | 16 | 8. E−16 | 7. E−18 | |
|
| 46394505..46395067 | 563 | PPP1R1AP2 | 1E+07 | ANKRD26P1 | 74273 | 16 | 12 | 3. E−23 | 4. E−23 | |
|
| 21972876..21973349 | 474 | KCNJ18 | 268263 | AC144838.2 | 83237 | 9 | 7 | 8. E−06 | 2. E−06 | |
|
| 26603641..26604283 | 643 | RP11‐846F4.11 | 3897955 | RP11‐260A9.1 | 377410 | 17 | 17 | 3. E−12 | 1. E−09 | |
|
| 107991..108643 | 653 | RP11‐683L23.6 | 13660 |
| 421 | 1 | 2 | 1. E−07 | 9. E−10 | |
|
| 110241..110848 | 608 |
| 0 | MIR8078 | 1407 | 2 | 2 | 9. E−09 | 2. E−08 | Rho‐Assoc'd Coiled‐Coil Prot. Kinase 1 ψgene1 |
|
| 31241472..31242039 | 568 | AC104301.2 | 339650 | DEFB115 | 15624 | 17 | 13 | 3. E−18 | 5. E−16 | |
|
| 7926020..7926634 | 615 | SNORA11 | 99794 | CH507‐338C24.3 | 174616 | 3 | 3 | 9. E−09 | 4. E−09 | |
|
| 8806909..8807490 | 582 | SNX18P10 | 5028 | bP−2189O9.1 | 38075 | 1 | 1 | 2. E−04 | 1. E−05 | |
|
| 10269991..10270557 | 567 | CH507‐216 K13.1 | 132986 | AP003900.6 | 57853 | 1 | 4 | 5. E−03 | 8. E−06 | |
|
| 10692593..10693162 | 570 | IGHV1OR21‐1 | 42757 | AP001464.4 | 2306513 | 4 | 2 | 4. E−15 | 6. E−15 | |
|
| 18896073..18896656 | 584 | AC008103.4 | 11390 | DGCR6 | 9371 | 1 | 1 | 2. E−02 | 4. E−05 | |
|
| 156030320..156030900 | 581 | DDX11L16 | 2442 | 1 | 1 | 1. E−06 | 1. E−06 | |||
|
| 10746657..10747217 | 561 | RNA5‐8SP6 | 546350 | RP1‐85D24.4 | 295504 | 16 | 8 | 5. E−05 | 1. E−03 | |
|
| 11305019..11305652 | 634 | AC134878.1 | 120061 | DUX4L16 | 1265 | 6 | 4 | 1. E−09 | 1. E−10 | |
|
| 11312236..11312823 | 588 | AC134882.1 | 3884 | DUX4L17 | 2097 | 4 | 5 | 1. E−08 | 8. E−09 | |
|
| 11324443..11324950 | 508 | DUX4L18 | 1619 | DUX4L19 | 7378 | 8 | 8 | 3. E−05 | 4. E−05 | |
|
| 11721743..11722304 | 562 | RP11‐295P22.2 | 247505 | RCC2P1 | 58747 | 8 | 8 | 1. E−09 | 2. E−08 | |
|
| 26638004..26638595 | 592 | FAM58CP | 10844 | CTBP2P1 | 3E+07 | 5 | 59 | 8. E−03 | 3. E−13 |
All listed peaks differed significantly from a uniform distribution at p < 0.05 to p < 6E–57; peak‐coincident genes (at zero distance from peaks) are indicated by bold font. Peak counts were not corrected for the 1.6‐fold higher protein and DNA recovery from AD relative to AMC hippocampus, since all reflect normalized data from 1 µg DNA.
RNA Fragments Recovered from AD, AMC Aggregates (RNA‐seq analysis)
| Chrom. | Region | Length | 5’ gene | 5’ dist. | 3’ gene | 3’ dist. | AD reads | AMC reads | AD/AMC reads | Chi2
| Transcript or encoded protein |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 633888..634164 | 277 | RP5‐857 K21.3 | 36389 |
| 0 | 515 | 1360 | 0.38 | 0.0001 | Transcribed processed pseudogene |
|
| 2281959..2282363 | 405 |
| 0 | MORN1 | 38889 | 1396 | 1967 | 0.71 | 0.0001 | Ski proto‐oncogene |
|
| 109100211..109100485 | 275 |
| 0 | RP5‐1065 J22.4 | 3049 | 131 | 98 | 1.34 | 0.05 | scaRNA, small Cajal‐body specific RNA2, guides mod'n of snRNAs |
|
| 244863775..244864066 | 292 | RP11‐11 N7.5 | 8277 |
| 0 | 509 | 653 | 0.78 | 0.004 | Heterog. Nuclear Ribonucleoprot. U (transripts 1, 3, 4, 8) |
|
| 32916221..32916538 | 318 |
| 0 | AL121656.5 | 10588 | 17 | 5 | 3.40 | 0.02 | Long Intergenic Non‐Protein Coding RNA 486 |
|
| 47335292..47335571 | 280 | CALM2 | 158690 |
| 0 | 2728 | 2093 | 1.30 | 0.0002 | Uncharacterized transcript |
|
| 148961908..148962183 | 276 |
| 0 | LYPD6B | 75923 | 3055 | 1856 | 1.65 | 0.0001 | Kinesin Family Member 5C (transcript KIF5C_2) |
|
| 181678574..181678849 | 276 | ITGA4 | 142386 |
| 0 | 107 | 60 | 1.78 | 0.001 | Ceramide Kinase Like |
|
| 231460607..231460888 | 282 | AC017104.2 | 7453 |
| 0 | 41 | 27 | 1.52 | N. S. | Ceroid‐Lipofuscinosis Neuronal Protein 5 (neurodegenerative lysosome storage disease) |
|
| 233275721..233275994 | 274 |
| 0 |
| 0 | 400/11 | 206/5 | 1.94/2.2 | 0.0001 | Autophagy Related 16‐Like 1 / scaRNA, small Cajal‐body RNA5 |
|
| 240713854..240714163 | 310 | RP11‐118 M12.2 | 12168 |
| 0 | 2806 | 4988 | 0.56 | 0.0001 | Kinesin family member 1A |
|
| 160514943..160515216 | 274 | RNU7‐136P | 42526 |
| 0 | 536 | 232 | 2.31 | 0.0001 | Karyopherin (Importin) Subunit Alpha 4 |
|
| 26204696..26204971 | 276 |
| 0 | HIST1H2BG | 11094 | 164 | 304 | 0.54 | 0.0001 | Histone 1 |
|
| 34071883..34072162 | 280 | MIR1275 | 71831 |
| 0 | 10689 | 5521 | 1.94 | 0.0001 | Glutamate Metabotropic Receptor 4 |
|
| 52995648..52995925 | 278 |
| 0 | ICK | 5353 | 32569 | 12138 | 2.68 | 0.0001 | 7SK RNA |
|
| 99408034..99408309 | 276 | COQ3 | 13829 |
| 0 | 206 | 135 | 1.53 | 0.001 | PNN Interact. Ser & Arg‐Rich Prot. (Pinin, desmosome assoc. prot.) |
|
| 5529123..5529444 | 322 | MIR589 | 33205 |
| 0 | 1210 | 1719 | 0.70 | 0.0001 | beta actin |
|
| 26200464..26200741 | 278 | CTB−119C2.1 | 25518 |
| 0 | 168 | 99 | 1.70 | 0.0002 | HnRNP A2/B1 |
|
| 9903986..9904242 | 257 | MIR597 | 162217 |
| 0 | 1667 | 1113 | 1.50 | 0.0001 | Long Intergenic Non‐Protein Coding RNA |
|
| 27604977..27605252 | 276 | GULOP | 15903 |
| 0 | 156 | 105 | 1.49 | 0.005 | Clusterin (a.k.a. ApoJ) |
|
| 35657748..35658022 | 275 | SIT1 | 6797 |
| 0 | 472 | 184 | 2.57 | 0.0001 | RNA Component of Mitoch. RNA Processing Endoribonuclease |
|
| 101799051..101799385 | 335 | NPM3 | 15637 |
| 0 | 683 | 432 | 1.58 | 0.0001 | Hyaluronidase =OGA, removes O‐GlcNAc modifications |
|
| 35663281..35663611 | 331 |
| 0 | KRT18P14 | 196637 | 1147 | 592 | 1.94 | 0.0001 | Tripartite Motif Containing 44 |
|
| 62841562..62841839 | 278 | RP11‐727F15.9 | 7518 |
| 0 | 304 | 149 | 2.04 | 0.0001 | WD Repeat Domain 74 |
|
| 65502716..65503064 | 349 | AP000769.7 | 4310 |
| 0 | 30539 | 16494 | 1.85 | 0.0001 | Metastasis Assoc. Lung Adenocarcinoma Transcr. 1 (Non‐Protein) |
|
| 111911504..111911780 | 277 | RPL37AP8 | 22029 |
| 0 | 228 | 216 | 1.06 | N. S. | Crystalin A beta, a small HSP |
|
| 123061064..123061339 | 276 | RPL31P47 | 9662 |
| 0 | 871 | 1512 | 0.58 | 0.0001 | Heat Shock Protein Family A (Hsp70) Member 8 (= HSC70) |
|
| 110281619..110281909 | 291 |
| 0 | RN7SL769P | 78542 | 433 | 225 | 1.92 | 0.0001 |
|
|
| 45975357..45975649 | 293 | AL445232.1 | 60203 |
| 0 | 372 | 240 | 1.55 | 0.0001 | Zinc Finger CCCH‐Type Containing 13 |
|
| 20343094..20343370 | 277 | SNORD126 | 16567 |
| 0 | 2313 | 634 | 3.65 | 0.0001 | Ribonuclease P RNA Component H1 |
|
| 23321579..23321860 | 282 |
| 0 | SLC22A17 | 24445 | 341 | 261 | 1.31 | 0.01 | Poly(A) Binding Protein Nuclear 1 |
|
| 49586595..49586871 | 277 | RNA5SP384 | 33846 |
| 0 | 22800 | 4958 | 4.60 | 0.0001 | Ribosomal protein, small subunit 29 |
|
| 49853648..49853923 | 276 | RNU6‐539P | 13820 |
| 0 | 24010 | 7554 | 3.18 | 0.0001 | RNA, cytoplasmic Signal Recognition Particle |
|
| 102084750..102085033 | 284 | RN7SL472P | 7277 |
| 0 | 186 | 94 | 1.98 | 0.0001 | HSP 90 family |
|
| 6452910..6453209 | 300 | FAM64A | 1440 |
| 0 | 671 | 520 | 1.29 | 0.004 | PITPNM 3, Phosphatidylinositol Transfer Protein Memb.‐ Assoc. |
|
| 19187969..19188246 | 278 | KYNUP1 | 18300 |
| 0 | 342 | 99 | 3.45 | 0.0001 | small nucleolar RNA |
|
| 44911190..44911459 | 270 | AC015936.3 | 6643 |
| 0 | 7051 | 8989 | 0.78 | 0.0002 | Glial Fibrillary Acidic Protein, GFAP ( |
|
| 49814124..49814400 | 277 | ACAA2 | 163 |
| 0 | 295 | 139 | 2.12 | 0.0001 | Transcribed processed pseudogene |
|
| 13298568..13298866 | 299 | CTC−250I14.1 | 139779 |
| 0 | 10268 | 5984 | 1.72 | 0.0001 | Calcium Voltage‐Gated Channel Subunit Alpha1 A |
|
| 36304598..36304871 | 274 |
| 0 | LINC00665 | 8195 | 556 | 164 | 3.39 | 0.0001 | Uncharacterized locus |
|
| 44907737..44908015 | 279 |
| 0 | CTB−129P6.7 | 1359 | 1028 | 1003 | 1.02 | N. S. | ApoE, Apolipoprotein E |
|
| 48645763..48646036 | 274 | DBP | 8324 |
| 0 | 407 | 573 | 0.71 | 0.0002 | Carbonic Anhydrase 11 |
|
| 49107777..49108115 | 339 |
| 0 | LIN7B | 6208 | 2096 | 1398 | 1.50 | 0.0001 | Small Nuclear Ribonucleoprotein U1 Subunit 70 |
|
| 23637606..23637888 | 283 | CST9 | 31729 |
| 0 | 573 | 742 | 0.77 | 0.003 | Cystatin C, Cystatin 3 |
|
| 41533110..41533383 | 274 | RP4‐620E11.5 | 150002 |
| 0 | 1245 | 864 | 1.44 | 0.0001 | Chromodomain Helicase DNA Binding Protein 6, CHDBP6 |
|
| 8258828..8259116 | 289 | RNA5‐8S5 | 1894 |
| 0 | 1200 | 132 | 9.09 | 0.0001 | Uncharacterized transcript |
|
| 8435771..8435981 | 211 |
| 0 | FP236383.1 | 96 | 207 | 12 | 17.25 | 0.0001 | Uncharacterized transcript |
|
| 26021821..26022101 | 281 | LLPHP2 | 258487 |
|
| 1477 | 702 | 2.10 | 0.0001 | Amyloid precursor protein, APP, A4 |
|
| 140784311..140784609 | 299 | LINC00632 | 11631 |
| 0 | 36675 | 62951 | 0.58 | 0.0001 | Cerebellar Degeneration Related Protein 1, CDRP1 |
All peaks shown were significant at p < 0.01; peak‐coincident genes (at zero distance from peaks) are indicated by bold font. Read ratios (AD/AMC) and p values for AD‐AMC differences were not corrected for 1.6‐fold higher RNA recovery from AD relative to AMC hippocampus, since all normalized RNA‐seq libraries used 1 µg RNA. “AD‐agg enriched” indicates proteins that were also found to be significantly enriched in AD aggregates relative to controls (Ayyadevara, Balasubramaniam, Parcon, et al., 2016).
DAVID Meta‐Analysis of Top RNA‐seq Peaks from Aggregates
| A. Genes from E3, E4 reads (55 DAVID IDs, implicating 16 clusters of terms sharing members) | ||||
|---|---|---|---|---|
| Cluster #, GO Term | Cluster Enrich. | Count | Fold Enrich. | Benjamini |
|
| 10.45 | 37 | 5.5 | 9E−21 |
| Acetylation | 10.45 | 31 | 4.2 | 3E−12 |
| Phosphoprotein | 10.45 | 35 | 2.0 | 8E−6 |
| Nucleus | 10.45 | 27 | 2.1 | 4E−4 |
|
| 8.65 | 31 | 4.2 | 3E−12 |
| Poly(A) RNA binding | 8.65 | 21 | 7.1 | 1E−10 |
| Ubiquitinlike (Ubl) conjugation | 8.65 | 20 | 5.5 | 3E−8 |
|
| 6.79 | 20 | 5.5 | 3E−8 |
| Cadherin binding, cell‐cell adhesion | 6.79 | 9 | 12 | 6E−5 |
| Cell‐cell adherens junction | 6.79 | 8 | 12 | 2E−5 |
|
| 3.58 | 5 | 30 | 6E−4 |
| Protein stabilization | 3.58 | 6 | 17 | 4E−3 |
|
| 2.77 | 8 | 22 | 2E−6 |
| Response to unfolded protein | 2.77 | 5 | 45 | 2E−3 |
| Protein refolding | 2.77 | 4 | 100 | 2E−3 |
| Stress response | 2.77 | 5 | 23 | 1E−3 |
| Chaperone | 2.77 | 6 | 14 | 1E−3 |
N.B.: Minor terms were omitted from each cluster. Cluster enrichment is the “Enrichment Score” from Functional Annotation Clustering under DAVID; fold enrichment is “Fold Change” per term; Benjamini indicates the false discovery rate, FDR, predicted by the Benjamini‐Hochberg procedure.
Human viral sequences in RNA and DNA fragments recovered from insoluble hippocampal aggregates
| Viral Genome Sequence (viral classification group) | AMC_RNAf Reads | AD_RNAf Reads | AMC_DNAf Reads | AD_DNAf Reads | AMC RNA/DNA | AD RNA/DNA | RNA (AD/AMC) | DNA (AD/AMC) |
|---|---|---|---|---|---|---|---|---|
| NC_022518.1_HERV_K113 (ssRNA‐RT) | 1,289 | 2,242 | 3,586 | 4,698 | 0.36 | 0.48 | 1.74 | 1.31 |
| NC_001806.1_Human_herpesvirus_1 (dsDNA) |
(162) | (327) | 192 | 183 | 0.84 | 1.79 | 2.02 | 0.95 |
| NC_001798.1_Human_herpesvirus_2 (dsDNA) | 12,806 | ***28,052 | 1,403 | (1,589) | 9.13 | 17.65 | 2.19 | 1.13 |
| NC_007605.1_Human_herpesvirus_4 (dsDNA) | (137) | 234 | 200 | 178 | 0.69 | 1.31 | 1.71 | 0.89 |
| NC_000898.1_Human_herpesvirus_6B (dsDNA) | (521) | ***1,476 | 2,411 | 2,627 | 0.22 | 0.56 | 2.83 | 1.09 |
| NC_012959.1_Human_adenovirus_54 (dsDNA) | 273 | 440 | (14) | (10) | 19.50 | 44.00 | 1.61 | 0.71 |
| NC_009823.1_Hepatitis_C_virus_type_2 (+ssRNA) | (5,492) | ***(15,501) | 19,181 | (22,028) | 0.29 | 0.70 | 2.82 | 1.15 |
| gi|60955|lcl|HPV6REF.1|_Human_papillomavirus_6_(HPV6) (dsDNA) | (82) | (140) | (151) | 218 | 0.54 | 0.64 | 1.71 | 1.44 |
| gi|9627396|lcl|HPV9REF.1|_Human_papillomavirus_9_(HPV9) (dsDNA) | (121) | ***(405) | 94 | (112) | 1.29 | 3.62 | 3.35 | 1.19 |
| gi|1491683|lcl|HPV72REF.1|_Human_papillomavirus_72_(HPV72) (dsDNA) | 334 | **(692) | (22) | (33) | 15.18 | 20.97 | 2.07 | 1.50 |
|
|
| *** |
|
|
Values in parentheses failed to meet one or more thresholds, but are included here for purposes of comparison. AD RNA counts differ from AMC by Chi‐squared test: **p<0.001; ***p<0.0001.
FIGURE 3Effects of EEF2 knockdown on the composition of aggregates in SY5Y‐APPSw cells. Results shown in each panel comprise data from 3 independent cell expansions treated with shRNA constructs targeting EEF2, or 2 scrambled RNAs for controls. Replicate experiments produced similar results. (A, B), Western‐blot quantitation of EEF2 knockdown efficacy, evaluated by EEF2 protein; efficacies of individual shRNAs (constructs a, b, c in Methods) are superimposed in B. (C, D), total RNA fragments in aggregates, quantified by gel staining with SYBR Gold. (E, F) Total DNA fragments in aggregates, quantified by ethidium bromide fluorescence. (G, H) Total aggregate protein, quantified by staining with SYPRO Ruby. p values shown here are based on 2‐tailed heteroscedastic t tests, for 3 – 4 experiments, combining data from shRNAs a – c